These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 10673513

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S.
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [Abstract] [Full Text] [Related]

  • 4. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P, Gehl J, Boesgaard M, Jensen TP, Jensen BW, Ejlertsen B.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [Abstract] [Full Text] [Related]

  • 5. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 6. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J, 303 Study Group.
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [Abstract] [Full Text] [Related]

  • 7. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [Abstract] [Full Text] [Related]

  • 8. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
    Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Aapro MS, Alaki M, Murawsky M, Riva A.
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
    [Abstract] [Full Text] [Related]

  • 12. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
    Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V, Manzione L, Conte PF.
    J Clin Oncol; 2006 Aug 20; 24(24):3912-8. PubMed ID: 16921042
    [Abstract] [Full Text] [Related]

  • 13. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY.
    Cancer; 1998 Jan 01; 82(1):134-40. PubMed ID: 9428489
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM, Smylie M, Mackey JR, Noel D, Paterson AH, al-Tweigeri T, Au D, Sansregret E, Delorme F, Riva A.
    Oncology (Williston Park); 1997 Aug 01; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R.
    Semin Oncol; 1998 Oct 01; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN.
    Clin Cancer Res; 2002 Nov 01; 8(11):3360-8. PubMed ID: 12429622
    [Abstract] [Full Text] [Related]

  • 18. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
    Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ.
    J Clin Oncol; 2002 Jul 15; 20(14):3114-21. PubMed ID: 12118025
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R, Sottotetti F, Trifirò G, Piazza E, Ferzi A, Gambaro A, Spinapolice EG, Pozzi E, Tagliaferri B, Teragni C, Bernardo A.
    Drug Des Devel Ther; 2015 Jul 15; 9():2189-99. PubMed ID: 25931813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.